A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

NCT07619443 | Not Yet Recruiting Phase 1 FDA Drug

• 2 other identifiers: 7262-003MK-7262-003
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Conditions

Healthy

Outcome Measures

Primary Outcomes (4)

• Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-7262

  Blood samples will be collected at multiple time points to estimate the AUC0-inf of MK-7262.

  Predose and at designated time points post-dose (up to 8 days)

• AUC0-inf of Enlicitide

  Blood samples will be collected at multiple time points to estimate the AUC0-inf of enlicitide.

  Predose and at designated time points post-dose (up to 8 days post-dose)

• Maximum Plasma Concentration (Cmax) of MK-7262

  Blood samples will be collected at multiple time points to estimate the steady-state Cmax of MK-7262.

  Predose and at designated time points post-dose (up to 8 days post-dose)

• Cmax of Enlicitide

  Blood samples will be collected at multiple time points to estimate the steady-state Cmax of enlicitide.

  Predose and at designated time points post-dose (up to 8 days post-dose)

Secondary Outcomes (14)

• Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of MK-7262

  Predose and at designated time points post-dose (up to 24 hours post-dose)

• Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-7262

  Predose and at designated time points post-dose (up to 8 days post-dose)

• Time to Maximum Plasma Concentration (Tmax) of MK-7262

  Predose and at designated time points post-dose (up to 8 days post-dose)

• Apparent Terminal Half-life (t1/2) of MK-7262

  Predose and at designated time points post-dose (up to 8 days post-dose)

• Apparent Clearance (CL/F) of MK-7262

  Predose and at designated time points post-dose (up to 8 days post-dose)

Study Arms (3)

MK-7262

EXPERIMENTAL

Participants will receive MK-7262 orally.

Drug: MK-7262

Enlicitide

EXPERIMENTAL

Participants will receive enlicitide orally.

Drug: Enlicitide

MK-7262 plus Enlicitide

EXPERIMENTAL

Participants will receive MK-7262 and enlicitide orally.

Drug: MK-7262; Drug: Enlicitide

Interventions

MK-7262 DRUG

Oral administration

MK-7262; MK-7262 plus Enlicitide

Enlicitide DRUG

Oral administration

Also known as: enlicitide decanoate, MK-0616

Enlicitide; MK-7262 plus Enlicitide

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is in good health before randomization
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive

You may not qualify if:

• Has a history or presence of clinically significant medical or psychiatric condition or disease
• Has a history of cancer

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Links

• Merck Clinical Trials Information

MeSH Terms

Interventions

MK-0616

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2026
• First Posted: June 2, 2026
• Study Start (Estimated): July 6, 2026
• Primary Completion (Estimated): September 5, 2026
• Study Completion (Estimated): September 12, 2026
• Last Updated: June 2, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share